The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year old. The approval is limited to children aged one to 11 years who weigh at least 15kg and who are inadequately controlled by, intolerant to, or who are not candidates for conventional medicinal therapy. This […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!